



April 11, 2017

Dear Nevada Senators,

The Myositis Association (TMA) is dedicated to protecting the lives of myositis patients while we seek a cure for this devastating disease.

We are concerned that SB 265 could set the precedent for price controls which can lead to restrictive formularies and create barriers to care for our member patients. Other concerns include:

- SB 265 requires non-profit organizations to report contributions made by drug manufacturers annually, to be posted on our website and imposes fines for non-compliance. This adds an additional reporting burden on our organization, taking away time and money from the activities that could ultimately lead to a cure and benefit our members.
- SB 265 may threaten patient's access to medications. If a 90-day advance notice on price increases is required then stockpiling by wholesalers will likely occur. These shortages have led to disruptions in the marketplace when tried previously and impair access to medications, threatening the health of those living with myositis.
- Medications are only one component of a larger, much more complicated healthcare system. SB 265 ignores the impact of pharmacy benefit managers (PBM). While one of the main purposes of PBMs is to leverage the number of people they represent for lower prices from drug makers, it is unclear whether they save patients any money at all.

Despite good intentions, we are not convinced that SB 265 will help patients or lower their out of pocket medication expenses.

Please keep our concerns in mind when considering this legislation.

  
Bob Goldberg  
Executive Director